Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | UGCG | Q16739 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31682193 | 0.87 | SOS1 (0.40) | HRH1AMY1AFTOUGCGGAA | |
| SCHEMBL31682201 | 0.85 | AMY1A (0.35) | HRH1AMY1AHTR6FTOUGCG | |
| SCHEMBL31682198 | 0.85 | USP2 (0.36) | GAAALDH1A1 | |
| SCHEMBL31682190 | 0.83 | LDHA (0.40) | AMY1AHTR6FTOL3MBTL1ALDH1A1 | |
| SCHEMBL31682173 | 0.83 | AMY1A (0.39) | AMY1AHTR6FTOTP53L3MBTL1 | |
| SCHEMBL31682178 | 0.83 | UGCG (0.34) | AMY1AHTR6FTOUGCGGAA | |
| SCHEMBL31682177 | 0.82 | UGCG (0.34) | UGCGMAPTALDH1A1 | |
| SCHEMBL31682194 | 0.82 | ALDH1A1 (0.37) | UGCGGAAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL31682181 | 0.81 | AMY1A (0.37) | HRH1AMY1AHTR6FTOMTOR | |
| SCHEMBL31682185 | 0.80 | ALDH1A1 (0.46) | GAAMAPTTP53L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289808-A1 | NOVEL CARBOXAMIDE REDOX DERIVATIVE OF INHIBITING BET PROTEIN AND COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISEASES USING THE SAME | BenoBio Co., Ltd (KR) | 2025-09-18 | — | — | US | disclosed |
| EP-4613329-A1 | COMPOUND FOR INHIBITING BRD PROTEIN | Benobio Co., Ltd. (KR) | 2025-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289808-A1 | NOVEL CARBOXAMIDE REDOX DERIVATIVE OF INHIBITING BET PROTEIN AND COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISEASES USING THE SAME | BET1, BRD4, BRD3 | HRH1 2872/4885METAP2 3764/4885AMY1A 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.